Financial Data
TXG Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
TXG10x Genomics, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum46
- Value34
- Quality59
- Risk resilience38
- Sentiment68
Financial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Oct 22, 2026.
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | $151.04M | $150.84M | $166.03M |
| Gross Profit | $112.5M | $106.18M | $113.05M |
| Operating Income | -$19.56M | -$17.05M | -$19.54M |
| Net Income | -$17.93M | -$13.47M | -$16.25M |
| EPS | -$0.14 | -$0.1 | -$0.13 |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Operating Cash Flow | $16.97M | $26.12M | $40.78M |
| Capital Expenditure | -$1.59M | -$1.6M | -$1.78M |
| Free Cash Flow | $15.39M | $24.52M | $39M |
| Net Cash Provided By Operating Activities | $16.97M | $26.12M | $40.78M |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Total Assets | $1.03B | $1.02B | $1.04B |
| Total Debt | $78.8M | $81.39M | $157.74M |
| Cash And Cash Equivalents | — | — | — |
| Total Liabilities | $204.52M | $201.44M | $245.04M |
| Total Stockholders Equity | $825.55M | $814.32M | $796.33M |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| P/E ratio | -68.46 | -53.07 | -31.37 |
| P/B ratio | 6.04 | 3.34 | 2.6 |
| P/S ratio | 33 | 18.06 | 12.48 |
| Debt To Equity | 0.1 | 0.1 | 0.2 |
| Free Cash Flow Yield | 0.31% | 0.90% | 1.88% |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| P/E ratio | -68.46 | -53.07 | -31.37 |
| P/B ratio | 6.04 | 3.34 | 2.6 |
| P/S ratio | 33 | 18.06 | 12.48 |
| Return On Equity | -2.17% | -1.65% | -2.04% |
| Debt To Equity | 0.1 | 0.1 | 0.2 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value |
|---|---|
| Pe | -101.66x |
| Pb | 9.44x |
| Gross Margin | 70.03% |
| Operating Margin | -14.33% |
| ROE | -9.33% |
| ROIC | -9.57% |
| Debt To Equity | 0.1 |
| FCF Yield | 1.59% |
As of Oct 21, 2026
| Metric | Value |
|---|---|
| Close | $75.59 |
| Volume | 3.12M |
| RSI (14) | 37.88 |
| MACD | -0.47 |
| MACD signal | 1.33 |
| MACD histogram | -1.8 |
| ADX (14) | 28.68 |
| SMA (50) | $71.85 |
| SMA (200) | $38.64 |
| ATR (14) | $6.43 |
| Historical volatility (annualized) | 94.62% |
| Volume (20-day average) | 4.19M |
As of Oct 21, 2026
| Metric | Value |
|---|---|
| Resilience score | 38/100 |
| Beta | 1.99 |
| Annual volatility | 74.62% |
| Max Drawdown | -28.52% |
| Sharpe Ratio | 2.68 |
| VaR (95%, 1-day) | -5.81% |
As of Oct 21, 2026
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
TXG Financial Data FAQ
What is 10x Genomics, Inc.'s revenue?
10x Genomics, Inc.'s revenue is one of the core financial data points for TXG. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is 10x Genomics, Inc.'s revenue growing?
Revenue growth shows whether 10x Genomics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is TXG's EPS?
TXG's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is 10x Genomics, Inc.'s net income?
10x Genomics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does 10x Genomics, Inc. generate?
Free cash flow shows how much cash 10x Genomics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does 10x Genomics, Inc. have?
Cash and debt help frame TXG's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.